Human papillomavirus infection in head and neck cancer: The role of the secretory leukocyte protease inhibitor

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1962-1968

  Hoffmann, Markus ^a   Quabius, Elgar S ^a   Tribius, Silke ^b   Hebebrand, Lena ^a   Görögh, Tibor ^a   Halec, Gordana ^c   Kahn, Tomas ^d   Hedderich, Jürgen ^e   Röcken, Christoph ^a   Haag, Jochen ^a   Waterboer, Tim ^c   Schmitt, Markus ^c   Giuliano, Anna R ^f   Kast, W Martin ^g  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d DEUTSCHE BANK AG   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Head and neck squamous cell carcinoma; Human papillomavirus; p16; Secretory leukocyte protease inhibitor

Indexed keywords

MESSENGER RNA; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; SLPI GENE; SMOKING HABIT; VIRUS DETECTION;

ADULT; AGED; DNA, VIRAL; DOWN-REGULATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LEUKOCYTES; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTEASE INHIBITORS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 84876261830     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2327     Document Type: Article

References (30)

1. Cordes C, Hasler R, Werner C, Gorogh T, et al: The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol 39: 185-191, 2011.
2. Hoffmann M, Ihloff AS, Gorogh T, et al: p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 127: 1595-1602, 2010.
3. Kreimer AR, Clifford GM, Boyle P, et al: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14: 467-475, 2005. (Pubitemid 40270113)
4. Smith EM, Ritchie JM, Summersgill KF, et al: Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 108: 766-772, 2004. (Pubitemid 38076410)
5. Termine N, Panzarella V, Falaschini S, et al: HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol 19: 1681-1690, 2008.
6. Hafkamp HC, Manni JJ, Haesevoets A, et al: Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 122: 2656-2664, 2008. (Pubitemid 351631366)
7. Hoffmann M, Gottschlich S, Gorogh T, et al: Human papilloma-viruses in lymph node neck metastases of head and neck cancers. Acta Otolaryngol 125: 415-421, 2005. (Pubitemid 40525006)
8. Hoffmann M, Gorogh T, Gottschlich S, et al: Human papilloma-viruses in head and neck cancer: 8 year-survival-analysis of 73 patients. Cancer Lett 218: 199-206, 2005. (Pubitemid 40164721)
9. Drannik AG, Henrick BM and Rosenthal KL: War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem Soc Trans 39: 1427-1432, 2011.
10. Fakioglu E, Wilson SS, Mesquita PM, et al: Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 82: 9337-9344, 2008.
11. Boudier C, Cadene M and Bieth JG: Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin. Biochemistry 29: 8451-8457, 1999.
12. Abe T, Kobayashi N, Yoshimura K, et al: Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 87: 2207-2215, 1991.
13. Franken C, Meijer CJ and Dijkman JH: Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 37: 493-498, 1989. (Pubitemid 19086846)
14. Jin FY, Nathan C, Radzioch D and Ding A: Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 7: 417-426, 1997. (Pubitemid 27131383)
15. Hiemstra PS: Novel roles of protease inhibitors in infection and inflammation. Biochem Soc Trans 30: 116-120, 2002.
16. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35, 2010.
17. Cole L, Polfus L and Peters ES: Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the U.S., 1995-2005. PLoS One 7: e32657, 2012.
18. Chan KH, Chan SC, Yeung SC, et al: Inhibitory effect of Chinese green tea on cigarette smoke-induced up-regulation of airway neutrophil elastase and matrix metalloproteinase-12 via antioxidant activity. Free Radic Res 46: 1123-1129, 2012.
19. Hoffmann M, Tribius S, Quabius ES, et al: HPV DNA, E6(*) I-mRNA expression and p16(INK4A) immunohistochemistry in head and neck cancer - how valid is p16(INK4A) as surrogate marker? Cancer Lett 323: 88-96, 2012.
20. Remmerbach TW, Brinckmann UG, Hemprich A, et al: PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol 30: 302-308, 2004. (Pubitemid 38649097)
21. Schmitt M, Bravo IG, Snijders PJ, et al: Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44: 504-512, 2006. (Pubitemid 43222244)
22. Schmitt M, Dondog B, Waterboer T, et al: Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 46: 1050-1059, 2008. (Pubitemid 351380000)
23. Halec G, Schmitt M, Dondog B, et al: Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer 132: 63-71, 2013.
24. McNeely TB, Shugars DC, Rosendahl M, et al: Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90: 1141-1149, 1997. (Pubitemid 27314150)
25. Woodham AW, Da Silva DM, Skeate JG, et al: The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One 7: e43519, 2012.
26. Wahl SM, McNeely TB, Janoff EN, et al: Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Dis 3 (Suppl 1): S64-S69, 1997. (Pubitemid 27242064)
27. Sun Z and Yang P: Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 5: 182-190, 2004. (Pubitemid 38262851)
28. Nakamura K, Takamoto N, Hongo A, et al: Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer. Oncol Rep 19: 1085-1091, 2008.
29. Alkemade HA, van Vlijmen-Willems IM, van Haelst UJ, et al: Demonstration of skin-derived antileukoproteinase (SKALP) and its target enzyme human leukocyte elastase in squamous cell carcinoma. J Pathol 174: 121-129, 1994. (Pubitemid 24318455)
30. Westin U, Nystrom M, Ljungcrantz I, et al: The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediators Inflamm 11: 7-12, 2002. (Pubitemid 34252541)